KRAS oncogene may be another target conquered in non‐small cell lung cancer ( NSCLC )-Reference-Cited by-同舟云学术

KRAS oncogene may be another target conquered in non‐small cell lung cancer ( NSCLC )

Published:2020-10-06 Issue:12 Volume:11 Page:3425-3435
ISSN:1759-7706
Container-title:Thoracic Cancer
language:en
Short-container-title:Thorac Cancer

Author:

Chen Hanxiao¹^ORCID,Zhao Jun¹^ORCID

Affiliation:

1. Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Departments of Thoracic Medical Oncology Peking University Cancer Hospital and Institute Beijing China

Publisher

Wiley

Subject

Pulmonary and Respiratory Medicine,Oncology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/1759-7714.13538

Reference100 articles.

1. Report of cancer epidemiology in China, 2015;Zheng RS;Zhonghua Zhong Liu Za Zhi,2019

2. Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer

3. Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non–Small-Cell Lung Cancer

4. PARAMOUNT: Final Overall Survival Results of the Phase III Study of Maintenance Pemetrexed Versus Placebo Immediately After Induction Treatment With Pemetrexed Plus Cisplatin for Advanced Nonsquamous Non–Small-Cell Lung Cancer

5. Pemetrexed, Bevacizumab, or the Combination As Maintenance Therapy for Advanced Nonsquamous Non–Small-Cell Lung Cancer: ECOG-ACRIN 5508

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Advancements in NSCLC;American Journal of Clinical Oncology;2024-02-20

2. WITHDRAWN: Oncogenic KRAS^G12Dextrinsically induces an immunosuppressive microenvironment in lung adenocarcinoma;2024-01-17

3. A Novel Combination of Sotorasib and Metformin Enhances Cytotoxicity and Apoptosis in KRAS-Mutated Non-Small Cell Lung Cancer Cell Lines through MAPK and P70S6K Inhibition;International Journal of Molecular Sciences;2023-02-22

4. Molecular Targets in Lung Cancer: Study of the Evolution of Biomarkers Associated with Treatment with Tyrosine Kinase Inhibitors—Has NF1 Tumor Suppressor a Key Role in Acquired Resistance?;Cancers;2022-07-07

5. KRAS p.G12C mutation occurs in 1% of EGFR-mutated advanced non-small-cell lung cancer patients progressing on a first-line treatment with a tyrosine kinase inhibitor;ESMO Open;2021-10